#News: Together with @StokeTx, we announced the first patient has been dosed in a Phase 3 study for our investigational therapy for Dravet syndrome. Read more:

We’re heading to the World Transplant Congress 2025 to share how we're helping to advance research for people living with a kidney transplant. Find us at booth #912 and visit our website to learn more about our work:

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

STARTING SOON: Join our Q2 2025 financial results live webcast at 8:30 AM ET. Join here: #Earnings $BIIB

#News: Read our Q2 2025 financial results here: #Earnings | $BIIB

#News: At #AAIC25, with Eisai we presented interim real-world data from two years of U.S. clinical experience with treatment in early Alzheimer’s disease. Learn more about this news:

#News: With Eisai, we presented two new data presentations at #AAIC25 for treatment in early Alzheimer’s disease (AD). These studies are a step forward for the AD community and in advancing care options for people living with AD. Read more:

#News: Today, we received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (#CHMP) for our postpartum depression (#PPD) treatment. Read the news here:

#News: We're thrilled to attend the Alzheimer's Association International Conference (#AAIC) 2025 to share updates from our Alzheimer's disease portfolio. Read more here:

#News: Today, we announced plans to invest $2 billion in our existing manufacturing footprint in North Carolina’s Research Triangle Park site to support our late-stage pipeline. Learn more about this news here:

#News: With @StokeTx, we announced new data from studies for an investigational medicine for Dravet Syndrome. Data were presented at the 16th European Paediatric Neurology Society Congress. Read the news here:

Biogen will report Q2 2025 financial results on July 31st before markets open in the U.S. Learn more: #Earnings $BIIB

#News: Exciting progress is underway as we begin the Phase 3 study of our investigational therapy for kidney disease in adults with primary membranous nephropathy (PMN). Learn more:

#News: We’re committed to driving innovation to help redefine what’s possible for the care of spinal muscular atrophy (SMA). We’re excited to share results from our ongoing research at the @CureSMA annual conference. Learn more about our findings:

#News: Our latest data from a phase 1 study evaluates our novel investigational SMA therapy and supports our efforts to address the needs of SMA patients. Read more about our research presented at the @CureSMA conference:

#News: We announced the initiation of the Phase 3 Pediatric Study of an investigational form of medicine for Friedreich ataxia (FA). Learn about this news:

Our CEO and leadership team shared key insights about our rare kidney disease program. As we continue to advance research, our goal is to bring additional care options to patient populations living with kidney disease. Listen now:

#News: Along with @ucb_news, we are pleased to share data from our phase 3 clinical trial evaluating our investigational lupus therapy at #EULAR2025. Read more:

#News: Today we’re hosting a virtual investor seminar to highlight the potential of our investigational therapy for a range of immune-mediated diseases, including three Phase 3 programs in rare kidney diseases. Learn more and join us at 10 a.m. ET:

Video description: Barcelona skyline with blue overlay. We look forward to sharing updates from our ongoing lupus research at EULAR 2025.

We’re heading to #EULAR2025 where we’ll share the latest updates from our ongoing lupus research!. We are excited to connect with rheumatologists & researchers to discuss the future of treatment. See how we’re addressing challenges: